These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27085161)

  • 1. Soluble sortilin is released by activated platelets and its circulating levels are associated with cardiovascular risk factors.
    Ogawa K; Ueno T; Iwasaki T; Kujiraoka T; Ishihara M; Kunimoto S; Takayama T; Kanai T; Hirayama A; Hattori H
    Atherosclerosis; 2016 Jun; 249():110-5. PubMed ID: 27085161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease.
    Hu D; Yang Y; Peng DQ
    Int J Cardiol; 2017 Jan; 227():61-65. PubMed ID: 27846466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.
    Karolczak K; Kamysz W; Karafova A; Drzewoski J; Watala C
    Pharmacol Res; 2013 Aug; 74():7-22. PubMed ID: 23665469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
    Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
    Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating sortilin level as a potential biomarker for coronary atherosclerosis and diabetes mellitus.
    Oh TJ; Ahn CH; Kim BR; Kim KM; Moon JH; Lim S; Park KS; Lim C; Jang H; Choi SH
    Cardiovasc Diabetol; 2017 Jul; 16(1):92. PubMed ID: 28728579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin dose increase from 75 to 150 mg suppresses red blood cell contribution to suboptimal platelet response to aspirin in patients with CAD.
    Karolczak K; Pietruszynski R; Drzewoski J; Kasznicki J; Watala C
    Cardiovasc Drugs Ther; 2013 Dec; 27(6):549-58. PubMed ID: 23963688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calprotectin and platelet aggregation in patients with stable coronary artery disease.
    Larsen SB; Grove EL; Pareek M; Kristensen SD; Hvas AM
    PLoS One; 2015; 10(5):e0125992. PubMed ID: 25970343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease.
    Larsen SB; Grove EL; Kristensen SD; Hvas AM
    Thromb Haemost; 2013 May; 109(5):920-9. PubMed ID: 23407706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin.
    Neergaard-Petersen S; Hvas AM; Grove EL; Larsen SB; Gregersen S; Kristensen SD
    PLoS One; 2015; 10(7):e0132629. PubMed ID: 26148094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet-bound cyclophilin A in patients with stable coronary artery disease and acute myocardial infarction.
    Seizer P; Fuchs C; Ungern-Sternberg SN; Heinzmann D; Langer H; Gawaz M; May AE; Geisler T
    Platelets; 2016; 27(2):155-8. PubMed ID: 26084004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased levels of platelet-derived soluble glycoprotein VI detected prior to the first diagnosis of coronary artery disease in HIV-positive individuals.
    Trevillyan JM; Gardiner EE; Andrews RK; Maisa A; Hearps AC; Al-Tamimi M; Crowe SM; Hoy JF
    Platelets; 2017 May; 28(3):301-304. PubMed ID: 27848272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
    Guthikonda S; Alviar CL; Vaduganathan M; Arikan M; Tellez A; DeLao T; Granada JF; Dong JF; Kleiman NS; Lev EI
    J Am Coll Cardiol; 2008 Aug; 52(9):743-9. PubMed ID: 18718422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homocysteine Levels Influence Platelet Reactivity in Coronary Artery Disease Patients Treated With Acetylsalicylic Acid.
    Verdoia M; Schaffer A; Pergolini P; Rolla R; Barbieri L; Bellomo G; Sinigaglia F; Marino P; Suryapranata H; De Luca G;
    J Cardiovasc Pharmacol; 2015 Jul; 66(1):35-40. PubMed ID: 25714593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet bound oxLDL shows an inverse correlation with plasma anaphylatoxin C5a in patients with coronary artery disease.
    Nording H; Giesser A; Patzelt J; Sauter R; Emschermann F; Stellos K; Gawaz M; Langer HF
    Platelets; 2016 Sep; 27(6):593-597. PubMed ID: 27025272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of diabetes on uric acid and its relationship with the extent of coronary artery disease and platelet aggregation: a single-centre cohort study.
    Verdoia M; Barbieri L; Schaffer A; Cassetti E; Nardin M; Bellomo G; Aimaretti G; Marino P; Sinigaglia F; De Luca G;
    Metabolism; 2014 May; 63(5):640-6. PubMed ID: 24606806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of endothelial and platelet activation are associated with high on-aspirin platelet reactivity in patients with stable coronary artery disease.
    Pettersen AÅ; Arnesen H; Opstad TB; Bratseth V; Seljeflot I
    Thromb Res; 2012 Sep; 130(3):424-8. PubMed ID: 22795340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease.
    Mason PJ; Chakrabarti S; Albers AA; Rex S; Vitseva O; Varghese S; Freedman JE
    Am J Cardiol; 2005 Nov; 96(10):1365-9. PubMed ID: 16275179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.
    Gremmel T; Xhelili E; Steiner S; Koppensteiner R; Kopp CW; Panzer S
    Atherosclerosis; 2014 Jan; 232(1):119-24. PubMed ID: 24401225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of low-grade inflammation on platelets in patients with stable coronary artery disease.
    Larsen SB; Grove EL; Würtz M; Neergaard-Petersen S; Hvas AM; Kristensen SD
    Thromb Haemost; 2015 Aug; 114(3):519-29. PubMed ID: 26062929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study.
    Kuliczkowski W; Radomski M; Gąsior M; Urbaniak J; Kaczmarski J; Mysiak A; Negrusz-Kawecka M; Bil-Lula I
    Biomed Res Int; 2017; 2017():9352015. PubMed ID: 28770228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.